Zoetis Stock: Why I’m Doubling Down On My Worst 2025 Pick (NYSE:ZTS)

Group 1 - Brendan, a co-founder of 1200 Pharma, has a strong background in organic synthesis and experience in both pharmaceutical and biotech sectors [1] - 1200 Pharma received significant investment, amounting to eight figures, indicating strong market interest and potential for growth [1] - Brendan's investment focus is primarily on biotechnology stocks, suggesting a strategic alignment with industry trends [1] Group 2 - The current investment strategy includes a diversified portfolio with broad-based ETFs to mitigate volatility, indicating a cautious approach to market fluctuations [3] - ZTS is identified as a potential strong-buy opportunity at a target price of $105 per share, which would provide a substantial margin of safety for investors [3] - The strategy may involve selling cash-secured puts to achieve an attractive cost basis, reflecting a tactical approach to investment in ZTS [3]